Exagen CEO sells 34,294 shares of Exagen stock

Published on 10/20/2026 at 13:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The sale funded tax withholding tied to vested equity awards. Exagen stock costs EUR 6.65 on October 20, 2026, with USD 180.0 million market value.

Ownership and quarterly growth

Exagen CEO John Aballi sold 34,294 shares on October 16, 2026.
Second-quarter revenue reached USD 19.94 million on August 4, 2026.
Exagen stock traded at EUR 6.65 at 1:18 p.m. CEST at Lang & Schwarz on October 20, 2026.

XGN, US30068X1037, Illustration mit AI erstellt.

Exagen (ISIN US30068X1037) CEO John Aballi sold 34,294 shares on October 16, 2026, according to Fidelity. The transaction was disclosed on October 19, 2026, and the filing said the sale funded tax withholding linked to vested equity awards.

Three dates define the story

On August 4, 2026, Exagen reported USD 19.94 million in second-quarter revenue and adjusted earnings per share of minus USD 0.13, versus consensus revenue of USD 17.80 million and a loss estimate of USD 0.19, according to MarketBeat. On October 13, 2026, TD Cowen raised its price target from USD 10.00 to USD 11.00, while Canaccord Genuity later raised its target from USD 9.00 to USD 11.00 on October 19, 2026. On October 16, 2026, Aballi sold the 34,294 shares.

What does the next report bring?

MarketBeat lists November 3, 2026, as Exagen's next quarterly reporting date and puts consensus revenue at USD 18.34 million, compared with USD 17.24 million in the year-earlier quarter. That implies a USD 1.10 million increase, or 6.38 percent, if the estimate is met. The contrast with the second quarter matters because the earlier quarter delivered USD 19.94 million in revenue.

Business remains centered on diagnostics

Exagen develops blood tests for autoimmune diseases under its AVISE brand, using proprietary CB-CAP technology to support diagnosis and monitoring. Its investor-relations page says the company targets approximately 5,000 rheumatologists in the United States through a testing and therapeutics sales model. The company reported a USD 180.0 million market capitalization on October 19, 2026, according to MarketBeat.

Stock trades in the afternoon

Exagen stock was trading at EUR 6.65 at Lang & Schwarz on October 20, 2026, at 1:18 p.m. CEST. The quote places the German-market indication alongside a company whose latest reported quarter generated USD 19.94 million in revenue and whose next report is dated November 3, 2026. The further course of trading is shown by the continuously updated real-time quote of Exagen stock.